ATE464911T1 - Zusammensetzungen zur behandlung von systemischer mastocytose - Google Patents

Zusammensetzungen zur behandlung von systemischer mastocytose

Info

Publication number
ATE464911T1
ATE464911T1 AT06764231T AT06764231T ATE464911T1 AT E464911 T1 ATE464911 T1 AT E464911T1 AT 06764231 T AT06764231 T AT 06764231T AT 06764231 T AT06764231 T AT 06764231T AT E464911 T1 ATE464911 T1 AT E464911T1
Authority
AT
Austria
Prior art keywords
systemic mastocytosis
compositions
mast cell
treating systemic
inhibitor
Prior art date
Application number
AT06764231T
Other languages
English (en)
Inventor
Peter Valent
Original Assignee
Peter Valent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter Valent filed Critical Peter Valent
Application granted granted Critical
Publication of ATE464911T1 publication Critical patent/ATE464911T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
AT06764231T 2005-07-20 2006-07-19 Zusammensetzungen zur behandlung von systemischer mastocytose ATE464911T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70109805P 2005-07-20 2005-07-20
PCT/EP2006/064431 WO2007010014A2 (en) 2005-07-20 2006-07-19 Compositions for treatment of systemic mastocytosis

Publications (1)

Publication Number Publication Date
ATE464911T1 true ATE464911T1 (de) 2010-05-15

Family

ID=37669166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06764231T ATE464911T1 (de) 2005-07-20 2006-07-19 Zusammensetzungen zur behandlung von systemischer mastocytose

Country Status (15)

Country Link
US (1) US8076321B2 (de)
EP (1) EP1909837B8 (de)
JP (1) JP5322639B2 (de)
KR (1) KR101351682B1 (de)
CN (1) CN101267837B (de)
AT (1) ATE464911T1 (de)
AU (1) AU2006271652B2 (de)
BR (1) BRPI0613863A2 (de)
CA (1) CA2615598C (de)
DE (1) DE602006013826D1 (de)
ES (1) ES2343542T3 (de)
PL (1) PL1909837T3 (de)
PT (1) PT1909837E (de)
RU (1) RU2429848C2 (de)
WO (1) WO2007010014A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2943418A1 (fr) * 2009-03-17 2010-09-24 Centre Nat Rech Scient Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
PL244930B1 (pl) * 2021-12-08 2024-04-02 Gdanski Univ Medyczny Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857040C2 (de) * 1998-12-10 2000-12-21 Siemens Ag Verfahren zur Detekton und Korrektur von Nichtlinearitäten hochfrequenter, spannungsgesteuerter Oszillatoren
US20030170720A1 (en) * 2001-01-23 2003-09-11 Van Der Kuyl Antoinette Cornelia Means and methods for treatment evaluation
WO2003002114A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
CA2538523A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
SG139747A1 (en) * 2003-11-18 2008-02-29 Novartis Ag Inhibitors of the mutant form of kit
US8247419B2 (en) 2005-06-09 2012-08-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein

Also Published As

Publication number Publication date
EP1909837B8 (de) 2010-06-02
RU2008105823A (ru) 2009-08-27
KR101351682B1 (ko) 2014-01-14
AU2006271652B2 (en) 2010-04-29
WO2007010014A3 (en) 2007-06-14
AU2006271652A1 (en) 2007-01-25
BRPI0613863A2 (pt) 2011-02-15
DE602006013826D1 (de) 2010-06-02
ES2343542T3 (es) 2010-08-03
JP2009501767A (ja) 2009-01-22
RU2429848C2 (ru) 2011-09-27
CN101267837A (zh) 2008-09-17
US20090221550A1 (en) 2009-09-03
CN101267837B (zh) 2010-12-15
EP1909837B1 (de) 2010-04-21
KR20080039915A (ko) 2008-05-07
CA2615598A1 (en) 2007-01-25
WO2007010014A2 (en) 2007-01-25
CA2615598C (en) 2014-04-15
EP1909837A2 (de) 2008-04-16
PL1909837T3 (pl) 2010-09-30
PT1909837E (pt) 2010-07-07
US8076321B2 (en) 2011-12-13
JP5322639B2 (ja) 2013-10-23

Similar Documents

Publication Publication Date Title
EA201100426A1 (ru) Бициклические ингибиторы киназы
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DK1660507T3 (da) Proteasominibitorer og metoder til anvendelse heraf
NI200800060A (es) Bencimidazoles sustituidos como inhibidores de cinasa.
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
ZA200709481B (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
EA201001648A1 (ru) Производные пиридазинона
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
ATE555108T1 (de) Polyamide zur behandlung des menschlichen papilloma-virus
ATE502935T1 (de) C-met-proteinkinasehemmer
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
DE60329326D1 (de) Tace inhibitoren
ATE464911T1 (de) Zusammensetzungen zur behandlung von systemischer mastocytose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1909837

Country of ref document: EP